Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Gawlick Rainer reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Rainer Gawlick received an award of 2,210 deferred stock units tied to common stock. The units were granted at no cash cost and increase his direct holdings to 46,093 common shares and units.
The deferred stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders, but must be retained until his service on the Board of Directors ends. This filing reflects routine, compensation-related equity, not an open-market purchase or sale.
WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Sven Wehrwein received an equity award of 2,210 deferred stock units on Common Stock. The award was granted at no cash cost per share and is a form of board compensation rather than an open-market purchase.
These deferred stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders, and must be held until his service on the Board of Directors ends. Following this grant, Wehrwein directly holds 34,505 shares of Proto Labs common stock.
Proto Labs director Donald G. Krantz reported an acquisition of company stock through a compensation grant. He received 2,210 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, reflecting an equity award rather than a market purchase.
These restricted stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders. After this award, Krantz directly holds 26,863 shares of Proto Labs common stock.
Proto Labs, Inc. reported the results of its Annual Meeting of Shareholders. Investors approved an amendment to the Amended and Restated 2022 Long-Term Incentive Plan, adding 395,000 shares available for equity awards to employees and directors.
Shareholders elected all seven board nominees, ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and supported executive compensation in an advisory vote. They also chose an annual frequency for future advisory votes on executive pay.
Proto Labs Inc: Schedule 13G/A amendment showing a passive investor position. Disciplined Growth Investors, Inc. reports beneficial ownership of 2,497,355 shares of Proto Labs common stock, representing 10.5% of the class as of 03/31/2026. The filing lists 2,351,815 shares with sole voting power and 2,497,355 shares with sole dispositive power.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported a series of transactions in company common stock. On May 11–12, 2026, he sold a total of 23,463 shares in open-market sales at weighted average prices generally between about $67 and $71 per share, under a pre-arranged Rule 10b5-1 trading plan adopted August 15, 2025. Over the same two days, he exercised employee stock options covering 14,960 shares at exercise prices of $33.52, $33.84, $39.61 and $59.40 per share, converting derivative awards into common stock. Following these transactions, he directly holds 18,683 Proto Labs shares.
PRLB-affiliated individual reported proposed sales of Common Stock under Form 144. The filing lists recent open-market disposals totaling specific transactions and multiple issuances from option exercises and restricted stock vesting recorded as issuable securities.
The filing names Michael Kenison as a seller with reported past three‑month sales on including 7,433 shares for $522,011, 200 shares for $14,000, and 5,000 shares for $332,315. The document also lists several option exercises and restricted stock vesting events with explicit share counts.
PRLB proposed sale notice: a brokered sale relating to an exercise of stock options and related 10b5-1 transactions. The excerpt lists 7,433 shares as securities to be sold on 05/11/2026 via exercise for cash, and records prior 10b5-1 sales of 200 shares for $14,000 on 05/07/2026 and 5,000 shares for $332,315 on 02/17/2026.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 200 shares of Common Stock at $70.00 per share in an open-market sale and exercised stock options to acquire 200 shares at strike prices of $33.52 and $33.84 per share.
The filing shows these trades were made under a pre-arranged 10b5-1 trading plan adopted on August 15, 2025. Following the transactions, he holds 27,186 Common Stock shares directly and continues to hold employee stock options, including grants with remaining balances of 7,455 and 7,612 options that vest annually starting on specified February 13 vesting dates.
PRLB submitted a Form 144 notice reporting a proposed sale of 200 shares of Common Stock tied to an exercise of stock options, with the transaction dated 05/07/2026 and cash used for the exercise. The filing also lists prior 10b5-1 sales by Michael Kenison of 5,000 shares on 02/17/2026 for $332,315.00.